Interim Phase 2 Analysis of Luspatercept in Treatment of Myelofibrosis-Associated Anemia
Data from an ongoing trial of luspatercept, an erythroid maturation agent, in patients with myelofibrosis and anemia shows promise of clinically significant activity with low level of grade 3/4 adverse effects.